Literature DB >> 9730463

Determination of the site of metabolism of total, free, and complexed prostate-specific antigen.

S Kilic1, S Yalcinkaya, E Guntekin, E Kukul, N Deger, M Sevuk.   

Abstract

OBJECTIVES: To determine the site of metabolism of total prostate-specific antigen (tPSA), free PSA (fPSA), and complexed PSA (cPSA).
METHODS: A total of 20 male patients, 50 years old or older, having a clinical indication for left and right heart catheterization were enrolled in this study. Selective blood samples were obtained from the infrarenal, infrahepatic, and suprahepatic inferior vena cava, renal vein, hepatic vein, superior vena cava, pulmonary artery, and femoral artery. cPSA concentration was accepted as the difference between tPSA and fPSA concentrations.
RESULTS: We found that tPSA and fPSA concentrations in the infrarenal inferior vena cava were significantly higher than in the systemic artery. There was no significant difference between the systemic artery and the infrarenal inferior vena cava for cPSA concentration. Although fPSA concentration decreased significantly across the renal circulation, the decreases in cPSA and tPSA concentrations were statistically insignificant. In the hepatic circulation, we found that tPSA, fPSA, and cPSA concentrations were significantly decreased. No decrease in tPSA, fPSA, and cPSA concentrations were noted across the pulmonary circulation.
CONCLUSIONS: Our results indicate that fPSA and tPSA are released into serum from the prostate but the prostate may not have a significant role in complex formation of PSA. In addition, the liver has a significant role in the elimination of tPSA, fPSA, and cPSA. By contrast, the kidneys have a significant role only in the elimination of fPSA. We also found that the lungs did not have a significant role in the elimination of tPSA, fPSA, or cPSA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9730463     DOI: 10.1016/s0090-4295(98)00208-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients.

Authors:  Ezequiel Becher; Alex Wang; Herbert Lepor
Journal:  Rev Urol       Date:  2019

3.  Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold.

Authors:  Minoru Kobayashi; Tomoya Mizuno; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Akinori Nukui; Hideyuki Abe; Yoshitatsu Fukabori; Masahiro Yashi; Takao Kamai
Journal:  Int J Clin Oncol       Date:  2019-08-22       Impact factor: 3.402

4.  Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010.

Authors:  Anqi Wang; Mariana Lazo; H Ballentine Carter; John D Groopman; William G Nelson; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-06-03       Impact factor: 4.254

5.  Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Authors:  David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens-Kristian Jensen; Tine Kold Olesen; Hans Lilja
Journal:  Clin Chem Lab Med       Date:  2012-11       Impact factor: 3.694

6.  Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Authors:  Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

7.  Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Authors:  Laila Bruun; Caroline Savage; Angel M Cronin; Jonas Hugosson; Hans Lilja; Anders Christensson
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

8.  Do the values of prostate specific antigen obtained from fresh and dried urine reflect the serum measurements?

Authors:  Hasan S Sağlam; Osman Köse; Fatma Ozdemir; Oztuğ Adsan
Journal:  Urol Ann       Date:  2013-04

9.  Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy.

Authors:  Zhien Zhou; Yinyan Xu; Qianyue Li; Weigang Yan; Yi Zhou; Zhibo Zheng; Hanzhong Li; Zhigang Ji
Journal:  Cancer Manag Res       Date:  2019-06-25       Impact factor: 3.989

10.  Effect of ejaculation on Serum Prostate-Specific Antigen concentration.

Authors:  Fatih Tarhan; Kadir Demir; Asuman Orcun; Ozlem Cakir Madenci
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.